Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline

Area of Science:

• Oncology
• Gastroenterology

Background:

• Anal cancer treatment requires evidence-based guidelines for optimal patient outcomes.
• Current treatment strategies involve chemoradiation, necessitating clear recommendations for chemotherapy agents.

Purpose of the Study:

• To provide evidence-based clinical practice guidelines for managing stage I-III anal cancer.
• To establish consensus on the most effective chemoradiation regimens.

Main Methods:

• A systematic literature review was conducted by the Minnesota Evidence-based Practice Center.
• An American Society of Clinical Oncology (ASCO) Expert Panel reviewed the evidence and formulated recommendations.

Main Results:

• Three randomized controlled trials and three nonrandomized studies informed the guideline.
• Mitomycin-C (MMC) with fluoropyrimidine (fluorouracil [FU] or capecitabine) is recommended as the radiosensitizing agent.
• Cisplatin with FU is an alternative, particularly for immunosuppressed patients due to reduced myelosuppression.

Conclusions:

• Mitomycin-C (MMC) plus fluoropyrimidine is the preferred radiosensitizing chemotherapy for anal cancer.
• Cisplatin plus FU is a viable alternative, especially for patients with immunosuppression.
• Routine induction or consolidation chemotherapy is not recommended for localized anal cancer.